Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Short-term Investments (2016 - 2025)

Historic Short-term Investments for CytomX Therapeutics (CTMX) over the last 11 years, with Q3 2025 value amounting to $109.4 million.

  • CytomX Therapeutics' Short-term Investments rose 4210.9% to $109.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $109.4 million, marking a year-over-year increase of 4210.9%. This contributed to the annual value of $62.6 million for FY2024, which is 6023.15% down from last year.
  • Latest data reveals that CytomX Therapeutics reported Short-term Investments of $109.4 million as of Q3 2025, which was up 4210.9% from $109.0 million recorded in Q2 2025.
  • CytomX Therapeutics' Short-term Investments' 5-year high stood at $168.1 million during Q3 2023, with a 5-year trough of $5000.0 in Q3 2021.
  • Moreover, its 5-year median value for Short-term Investments was $99.1 million (2022), whereas its average is $92.6 million.
  • Per our database at Business Quant, CytomX Therapeutics' Short-term Investments crashed by 9999.65% in 2021 and then skyrocketed by 198498000.0% in 2022.
  • Quarter analysis of 5 years shows CytomX Therapeutics' Short-term Investments stood at $99.7 million in 2021, then decreased by 0.44% to $99.3 million in 2022, then surged by 58.52% to $157.3 million in 2023, then crashed by 60.23% to $62.6 million in 2024, then soared by 74.91% to $109.4 million in 2025.
  • Its last three reported values are $109.4 million in Q3 2025, $109.0 million for Q2 2025, and $32.3 million during Q1 2025.